En del af Watch Medier

MedWatchtirsdag7. februar 2023

  • Søg
  • Log ind
  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Søg
  • Log ind
  • Seneste
  • Søg
  • Log ind
  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Digital sundhed
  • Samfund
  • Mennesker
  • Sygdom & Sundhed
20.08.2013kl. 12.25

”It’s not data that knocks my socks off”

According to analyst Søren Løntoft Hansen a number of factors mean that MannKind’s new inhalable insulin product is not likely to be a great threat to companies like Novo Nordisk.
Foto: Sydbank/PR
Foto: Sydbank/PR
by Stefan Singh Kailay

Lack of efficacy, a lack of a partner and a similar product that has been linked to lung cancer - those are the three main reasons why MannKind’s inhalable insulin product, Afrezza, is not likely to have a great impact on the market for diabetes treatments, according to Sydbank analyst, Søren Løntoft Hansen.

Last week, MannKind presented data from two phase III studies with the medicine, but even though the share went up significantly, and even though the company proclaimed the data to be very strong, Søren Løntoft Hansen is not impressed.

“It’s not data that knocks my socks off, I have to admit. They do deliver a decrease in long-term blood sugar, but it is only half of what Novolog/NovoRapid manages. The smaller drop might also explain the fewer incidences of low blood sugar from Afrezza. You also lose a lot of the effect by taking your insulin through the lungs rater than by injection. It’s not impressive, and it’s not something that sways me,” he tells Medwatch.

None of the majors

Pfizer’s inhalable insulin, Exubera, was pulled from the market in 2007 after a year, partly due to disappointing sales figures and partly due to a study that showed an increased risk of developing lung cancer.

“At that time, all the three majors, Novo Nordisk, Eli Lilly, and Sanofi, were developing inhalable insulins, and they all gave it up with the very simple reason that it would never result in anything. I think a great many diabetes doctors have the risk of lung cancer in the back of their minds.”

Moreover, MannKind does not have a partner and, keeping past experiences in mind, the analyst does not believe Eli Lilly, Novo Nordisk or Sanofi would be interested in partnering with MannKind. That will also offer greater challenges for the company in terms of distribution and marketing.

“They might be able to market a drug, but at the end of the day it’s about efficacy, and I don’t belive the efficacy of Afrezza is good compared with injectable insulins.”

No paradigm shift

Novo Nordisk’s CSO, Mads Krogsgaard Thomsen, has previously explained to Medwatch that the company has conducted surveys showing patients using Pfizer’s product found it to be more inconvenient than injecting the insulin twice a day. However, the analyst does not think convenience is a barrier anymore.

“That barrier belongs to the past, because the inhaler that came with Pfizer’s product was a very large and unhandy apparatus that had to be disassembled and washed after use. But my impression is that the inhaler MannKind uses is far more convenient and easy to use,” he says, but points out:

“If you think this will result in a paradigm shift in the use of fast-acting insulins, you are setting yourself up for a disappointment.”

- translated by Martin Havtorn Petersen

Want to receive the latest news from Medwatch straight in your e-mail inbox? Sign up for our free english newsletter below.

Tilmeld dig vores nyhedsbrev

Vær på forkant med udviklingen. Få den nyeste viden fra branchen med vores nyhedsbrev.

!
Nyhedsbrevsvilkår

Forsiden lige nu

Foto: Jacob Ehrbahn
Medicinal & Biotek

Overlæge opdagede multiresistente bakterier i antibiotikum: "Det, vi havde frygtet, holdt faktisk stik"

At antibiotikum har smittet patienter med multiresistente bakterier er ifølge læge uden fortilfælde.
  • Lægemiddelstyrelsen tilbagekalder Sandoz-antibiotika efter en række smittetilfælde

For abonnenter

Søren Nielsen, adm. direktør i Demant | Foto: Demant / Pr
Høreapparater

Demant har svært ved at forudsige udviklingen på genåbnet kinesisk marked

For abonnenter

Foto: Jens Dresling
Medicinal & Biotek

Lundbecks nøgleprodukter skuffer på grund af Brintellix

For abonnenter

Lars Fruergaard, koncernchef i Novo Nordisk | Foto: Stine Bidstrup / Ritzau Scanpix
Medicinal & Biotek

Novo Nordisk-topchef ser Wegovy-lancering på større markeder i Europa i 2023

Lundbecks hovedkvarter ligger i Valby i København. | Foto: Lundbeck / Pr
Medicinal & Biotek

Lundbeck nedskriver Vyepti-lagre, laver rekord og forventer fortsat milliardvækst

For abonnenter

Foto: Florian Olivo / Unsplash
Høreapparater

Demants headset-forretning fortsat ramt af svagt gaming-marked

Job

  • Application Manager

  • Erfaren Patentrådgiver

  • Clinical Operational Associate

  • Senior Clinical Project Manager

  • Commercial Director

  • Lead Data Architect

  • Application Manager

  • Medical Advisor (Metabolism)

  • Sr. Director, Drug Safety Physician

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Senior Laboratory Technician

  • Specialist til udbud på lægemidler til danske sygehuse

  • Leder til Amgros’ kvalitetsteam

  • Regulatory Affairs Professional

  • Supply Chain Manager

Se flere jobs

Seneste nyt

  • Overlæge opdagede multiresistente bakterier i antibiotikum: "Det, vi havde frygtet, holdt faktisk stik" – 20.28
  • Novo Nordisk-topchef ser Wegovy-lancering på større markeder i Europa i 2023 – 18.48
  • Demant har svært ved at forudsige udviklingen på genåbnet kinesisk marked – 15.16
  • Demants headset-forretning fortsat ramt af svagt gaming-marked – 14.48
  • Sydbank forudser medvind til Lundbeck efter god årsafslutning og længere prognose – 13.13
  • Lundbecks nøgleprodukter skuffer på grund af Brintellix – 13.01
  • Lundbeck nedskriver Vyepti-lagre, laver rekord og forventer fortsat milliardvækst – 12.39
  • WS Audiology ser ingen negativ påvirkning af traditionelle produkter efter OTC-lancering – 12.28
  • Analytiker sætter fokus på nøgleprodukter og ny prognose i oonsdagens regnskab fra Lundbeck – 12.18
  • Demant ser fornuft i konsolidering blandt store producenter af høreapparater – 12.16
  • Ambu holder igen med nye lanceringer – 10.56
  • FDA godkender ny generation af Ambu-produkt til lungeundersøgelser – 10.01
  • Demant vil ikke tilbagekøbe aktier i 2023 – 09.31
  • Demant venter at lukke salg af implantatforretning i andet kvartal – 09.15
  • Demant ser gode opkøbsmuligheder og venter høj gæld ved årsafslutning – 08.07
Flere nyheder

Job

  • Application Manager

  • Erfaren Patentrådgiver

  • Clinical Operational Associate

  • Senior Clinical Project Manager

  • Commercial Director

  • Lead Data Architect

  • Application Manager

  • Medical Advisor (Metabolism)

  • Sr. Director, Drug Safety Physician

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Senior Laboratory Technician

  • Specialist til udbud på lægemidler til danske sygehuse

  • Leder til Amgros’ kvalitetsteam

  • Regulatory Affairs Professional

  • Supply Chain Manager

Se flere jobs

Watch Job

  • Erfaren fuldmægtig eller advokat med interesse for danske og internationale virksomheder

  • Business Intelligence Specialist

  • Revisor med minimum et par års erfaring

  • Jurister søges til Corporate Legal i Danmarks Eksport & Investeringsfond

  • Tilbudschef - NCC Renovering Vest

Se flere jobs

Kolofon

MedWatch
Søg

Sektioner

  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Digital sundhed
  • Samfund
  • Mennesker
  • Sygdom & Sundhed
  • Sitemap
  • RSS feeds

Redaktør

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tlf.: +45 3330 8387

  • Om MedWatch

Ansv. chefredaktør

Anders Heering

Udgiver

JP/Politikens Hus A/S

Annonceafdeling

annoncering@infowatch.dk

Tlf.: +45 7077 7441

Annoncering

Jobannoncering

job@infowatch.dk

Tlf.: +45 7077 7441

Job

Abonnement

Prøv MedWatch gratis eller få tilbud på et abonnement, der passer til lige netop dig eller din virksomhed.

medwatch@infowatch.dk

Tlf.: +45 7077 7441

Læs mere om abonnement her

Adresse

MedWatch

Rådhuspladsen 37

1785 København V

Tlf.: +45 3330 8370

Retningslinjer

  • Persondatapolitik

Copyright © MedWatch — Alt materiale på denne side er omfattet af gældende lov om ophavsret

Microsoft er i gang med at udfase Internet Explorer – det er vi derfor også.
Vi anbefaler en af følgende browsere for en bedre oplevelse. Klik på et af ikonerne for at downloade en ny browser.

Med venlig hilsen,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge